Acute dystonia, akathisia, and parkinsonism induced by ziprasidone

American Journal of Therapeutics

Volumn 21, Issue 2, 2014, Pages

  Praharaj, Samir Kumar ^a   Jana, Amlan Kusum ^b   Sarkhel, Sujit ^c   Sinha, Vinod Kumar ^d  

^a KASTURBA MEDICAL COLLEGE   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

^c INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^d CENTRAL INSTITUTE OF PSYCHIATRY   (India)

Author keywords

Acute dystonia; Akathisia; Atypical antipsychotic; Parkinsonism; Ziprasidone

Indexed keywords

CLONAZEPAM; PROPRANOLOL; SERTRALINE; TRIHEXYPHENIDYL; ZIPRASIDONE;

ADD ON THERAPY; ADULT; AKATHISIA; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; CERVICAL DYSTONIA; DELUSION; DISTRESS SYNDROME; DRUG DOSE REDUCTION; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEART PALPITATION; HUMAN; MALE; MENTAL HEALTH; PANIC; PARANOID SCHIZOPHRENIA; PARKINSONISM; PRIORITY JOURNAL; PROPENSITY SCORE; SWEATING; TREMOR; XEROSTOMIA;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; HUMANS; MALE; PARKINSONIAN DISORDERS; PIPERAZINES; THIAZOLES;

EID: 84896399404     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318230ae52     Document Type: Article

References (27)

1. Crane DL. Ziprasidone as an augmenting agent in the treatment of anxiety spectrum disorders. CNS Spectr. 2005;10:176-179.
2. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exper Ther. 1995;275:101-113.
3. Joyce AT, Harrison DJ, Loebel AD, et al. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res. 2006;83:285-292.
4. Kane JM, Khanna S, Rajadhyaksha S, et al. Efficacy and tolerability of ziprasidone in patients with treatmentresistant schizophrenia. Int Clin Psychopharmacol. 2006; 21:21-28.
5. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract. 2002;8:81-97.
6. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20:491-505.
7. Mason MN, Johnson CE, Piasecki M. Ziprasidone-induced acute dystonia. Am J Psychiatry. 2005;162:625-626.
8. Yumru M, Savas HA, Selek S, et al. Acute dystonia after initial doses of ziprasidone: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:745-747.
9. Ramos AE, Shytle RD, Silver AA, et al. Ziprasidoneinduced oculogyric crisis. J Am Acad Child Adolesc Psychiatry. 2003;42:1013-1014.
10. Ziegenbein M, Schomerus G, Kropp S. Ziprasidoneinduced Pisa syndrome after clozapine treatment. J Neuropsychiatry Clin Neurosci. 2003;15:458-459.
11. Keck ME, Müller MB, Binder EB, et al. Ziprasidone-related tardive dyskinesia. Am J Psychiatry. 2004;161:175-176.
12. Papapetropoulos S, Wheeler S, Singer C. Tardive dystonia associated with ziprasidone. Am J Psychiatry. 2005; 162:2191.
13. Arbuck DM. 12,800-mg ziprasidone overdose without significant ECG changes. Gen Hosp Psychiatry. 2005;27: 222-223.
14. Gómez-Criado MS, Bernardo M, Florez T, et al. Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. Pharmacotherapy. 2005;25:1660-1665.
15. Weinstein SK, Adler CM, Strakowski SM. Ziprasidoneinduced acute dystonic reactions in patients with bipolar disorder. J Clin Psychiatry. 2006;67:327-328.
16. Oral ET, Altinbas K, Demirkiran S. Sudden akathisia after a ziprasidone dose reduction. Am J Psychiatry. 2006;163:546.
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
18. Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol. 2007;27:35-45.
19. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008; 28:203-209.
20. Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
21. Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9:410-418.
22. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996; 57:449-454.
23. Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:741-748.
24. Walker L. Sertraline-induced akathisia and dystonia misinterpreted as a panic attack. Psychiatr Serv. 2002;53: 1477-1478.
25. Lipinski JF Jr, Mallya G, Zimmerman P, et al. Fluoxetineinduced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989;50:339-342.
26. Mullins DC, Shaya FT, Zito JM, et al. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res. 2006;83:277-284.
27. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825.